GlassScriptPhysician profile
Pradnya Patil
NPI 1922310598
$47,942.16
in general payments reported to CMS, 2019-2025
18 companies · $38K in 2025
The $38K reported for 2025 was more than what 95% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $217 · 2020: $90.50 · 2021: $4,330 · 2022: $1,570 · 2023: $49.62 · 2024: $3,672 · 2025: $38K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24K · Travel and Lodging: $10K · Consulting Fee: $5,348 · Food and Beverage: $1,693 · Education: $19.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24,420.00 |
| Travel and Lodging | $10,254.00 |
| Consulting Fee | $5,348.00 |
| Food and Beverage | $1,692.77 |
| Education | $19.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $37,909.98 | 2019-2025 | Rybrevant, Carvykti |
| Astrazeneca Pharmaceuticals LP | $4,137.00 | 2021-2025 | Calquence |
| E.R. Squibb & Sons, L.L.C. | $1,967.10 | 2024 | Opdivo |
| Jazz Pharmaceuticals INC. | $1,614.65 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,428.00 | 2024 | |
| Novocure Gmbh | $200.00 | 2022 | |
| Abbvie INC. | $104.50 | 2024-2025 | |
| Insmed, INC. | $90.50 | 2020 | |
| Tempus Ai, INC | $81.21 | 2024-2025 | Xt Cdx |
| Sanofi-Aventis U.S. LLC | $74.99 | 2019 | |
| Daiichi Sankyo INC. | $69.32 | 2023-2025 | Enhertu |
| Intuitive Surgical, INC. | $68.91 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $53.39 | 2024-2025 | Lynozyfic, Libtayo |
| Merck Sharp & Dohme LLC | $38.32 | 2023-2024 | Keytruda |
| Incyte Corporation | $29.36 | 2025 | Monjuvi |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $25.89 | 2025 | Braftovi, Lorbrena, Mektovi |
| Takeda Pharmaceuticals U.S.A., INC. | $25.61 | 2024 | Alunbrig |
| Celgene Corporation | $23.43 | 2024 | Pomalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pradnya Patil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.